Blueprint Medicines Corporation
blueprintmedicines.comTotal trials
31
Active
7
Phase 3
2
Total enrollment
5,057
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Avapritinib | — | 12 | |||||
| Elenestinib | — | — | — | — | 2 | ||
| BLU-808 | — | — | — | — | 3 |
Next readouts
- 2026-12-31
- 2027-06-23
- 2027-12-31
- 2028-12-01
- 2032-09-30
Top conditions
- Indolent Systemic Mastocytosis4
- Carcinoma, Non-Small-Cell Lung4
- Respiratory Tract Neoplasms4
- Neoplasms4
- Neoplasms by Site4
- Lung Diseases4
- Carcinoma, Bronchogenic4
- Carcinoma4
Frequently asked questions about Blueprint Medicines Corporation
- How many clinical trials does Blueprint Medicines Corporation have on ClinicalTrials.gov?
- Blueprint Medicines Corporation is listed as the lead sponsor on 31 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Blueprint Medicines Corporation's trials are in Phase 3?
- 2 of Blueprint Medicines Corporation's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Blueprint Medicines Corporation focus on?
- Blueprint Medicines Corporation's most-studied conditions on ClinicalTrials.gov are Indolent Systemic Mastocytosis, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site.
- When are Blueprint Medicines Corporation's next clinical trial readouts?
- Blueprint Medicines Corporation has 5 upcoming primary-completion readouts tracked here; the soonest is “Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)”, expected around 2026-12-31.